Antonio Passaro: This scientific journey has not only been immensely interesting but exceptionally fruitful

Antonio Passaro, Medical Oncologist at the European Institute of Oncology, shared on LinkedIn:

“Delighted to have the opportunity to reconnect with numerous colleagues from the dynamic GCC area – traveling across Qatar, Kuwait, Bahrain, Oman, and Dubai!

I had the pleasure to discuss the evolution of treatment scenario for patients with EGFR mutant lung cancer, focusing on the results of many trials presented in the last months (MARIPOSA, FLAURA2, MARIPOSA-2, PAPILLON, Herthena-Lung1, Tropion-Lung5, INSIGHT-2….)

Waiting for FDA, EMA & local approvals, we discussed how these breakthroughs are on the verge of transforming, in the near future, the therapeutic landscape for patients with lung cancer harboring EGFR mutations, encompassing both common and exon20ins variants – a long-overdue revolution.

After years of unwavering dedication to research, it’s genuinely fulfilling to witness how these studies are poised to redefine the future of patient care, improve their prognosis, and look ahead with great confidence.

This scientific journey has not only been immensely interesting but exceptionally fruitful, underscoring our unwavering commitment to enhancing therapeutic prospects for our patients. Thrilled about the positive impact our collective efforts are set to deliver!

Thanks to Osama Kandil and the entire Johnson & Johnson Innovative Medicine for their support and dedication.
IEO Istituto Europeo di Oncologia”

Source: Antonio Passaro/LinkedIn